

**RECEIVED  
CENTRAL FAX CENTER****JUN 02 2008**

Docket No.: ALEX-P03-060

Application No. 10/736,188  
Amendment dated June 2, 2008  
Reply to Office Action of April 3, 2008

**AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-18. (Canceled)

19. (Currently amended) A method of inhibiting downregulation of IL-2 or IFN-gamma in a treating CLL patient comprising:  
determining whether OX-2/CD200 is upregulated in a human subject afflicted with CLL; and  
administering to those subjects in which OX-2/CD200 is upregulated an antibody or antigen-binding fragment thereof that binds to human OX-2/CD200 which is upregulated on CLL cells, said antibody or antigen-binding fragment thereof being administered in an amount effective to inhibit an the downregulation of IL-2 or IFN-gamma ~~immune-suppressing effect of OX-2/CD200~~ in said subject.

20. (Canceled)

21. (Previously presented) A method as in claim 19, wherein the antibody is a monoclonal antibody.

22-42. (Canceled)

43. (Previously presented) A method as in claim 19, wherein the antibody or antigen-binding fragment thereof comprises a light chain CDR1 comprising the sequence set forth in SEQ ID NO: 12; a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 23; a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 37; a heavy chain CDR1 comprising the sequence

Application No. 10/736,188  
Amendment dated June 2, 2008  
Reply to Office Action of April 3, 2008

Docket No.: ALEX-P03-060

set forth in SEQ ID NO: 55; a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 74; and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 93.

44. **(Withdrawn)** A method as in claim 19, wherein the antibody or antigen-binding fragment thereof comprises a light chain CDR1 comprising the sequence set forth in SEQ ID NO: 5; a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 21; a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 29; a heavy chain CDR1 comprising the sequence set forth in SEQ ID NO: 50; a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 69; and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 88.

45. **(Withdrawn)** A method as in claim 19, wherein the antibody or antigen-binding fragment thereof comprises a light chain CDR1 comprising the sequence set forth in SEQ ID NO: 13; a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 23; a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 38; a heavy chain CDR1 comprising the sequence set forth in SEQ ID NO: 56; a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 75; and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 94.

46-51. **(Canceled)**

52. **(Previously presented)** A method as in claim 19, wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')<sub>2</sub>s.

53. **(Previously presented)** A method as in claim 43, wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')<sub>2</sub>s.

54. **(Withdrawn)** A method as in claim 44 wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')<sub>2</sub>s.

Application No. 10/736,188  
Amendment dated June 2, 2008  
Reply to Office Action of April 3, 2008

Docket No.: ALEX-P03-060

55. **(Withdrawn)** A method as in claim 45 wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')<sub>2</sub>s.

56-70. **(Not Entered)**

71-78. **(Cancelled)**